Fundz

FibroBiologics

Houston, Texas, United States · Biotechnology, Health Care, Therapeutics · 15 employees

FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics,

Funding history

  • Seed · $3.0M · Jun 2026
  • Seed · $1.7M · Dec 2025
  • Seed · $1.5M · Dec 2025
  • Seed · $4.0M · Dec 2025
  • Funding Round · $5.0M · Jul 2025

Recent signals

  • Aug 24, 2026: Leigh Steinberg Appointed as Class II Director at FibroBiologics
  • Aug 20, 2026: SEC 8-K (5.02): On August 20, 2026, FibroBiologics, Inc. appointed Leigh Steinberg as a Class II director of the Board, effective immediately. He will serve until the 2028 annual meeting of stockholders. Mr. Steinberg's compensation will align with the other non-employee directors according to the Company's Non-Employee Director Compensation Policy. Importantly, there are no disclosed transactions or arrangements requiring further regulatory disclosure linked to Mr. Steinberg's appointment. This strategic move signifies a continued focus on strong governance and leadership within the organization.
  • Jun 29, 2026: Raised $3.0M in Seed
  • Dec 16, 2025: Raised $1.7M in Seed
  • Dec 03, 2025: Raised $1.5M in Seed
  • Dec 03, 2025: Raised $4.0M in Seed
  • Nov 18, 2025: SEC 8-K (1.01): On November 18, 2025, FibroBiologics, Inc. entered into a securities purchase agreement with a single investor to conduct a registered direct offering. Under this agreement, the company will issue and sell 3,540,000 shares of its common stock at a price of $0.3303 per share, along with pre-funded warrants to purchase up to an additional 8,570,203 shares of common stock. This financing will raise significant funds for the company and is part of its strategy to enhance liquidity and support ongoing operations. The offering price reflects a small discount to the market value, indicating an attractive opportunity for the investor involved.
  • Jul 31, 2025: Raised $5.0M in Funding Round

See plans & pricing → Track FibroBiologics’s funding, hiring and signals, with verified contacts, on Fundz.

Fundz watches FibroBiologics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.